宏光半導體(06908.HK)向朱共山配股及發行認股權證 最多籌4億元
宏光半導體(06908.HK)公布,向投資人、協鑫科技(03800.HK)創辦人朱共山配售6,000萬股,每股配售價為3元,較昨日(29日)收市價3.86元折讓約22.28%,料淨集資約1.8億元。另向朱共山發行認股權證,初步最多可認購6,000萬股,每份認股權證行使價為3.68元,較昨日收市價折讓約4.66%,料淨集資最多約2.21億元。
事實上,於今年8月初宏光半導體已與朱共山訂立投資協議。涉及上述股份相當於經配發及發行認購股份及認股權證股份擴大後公司股本共約17.32%。
公司指出,擬將配售事項及認股權證認購事項之最高所得款項約4.01億元用於發展集團之氮化鎵(GaN)業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.